Previous 10 | Next 10 |
aTyr Pharma (NASDAQ:LIFE) is scheduled to announce Q3 earnings results on Wednesday, November 10th, after market close. The consensus EPS Estimate is -$0.57 (+16.2% Y/Y) and the consensus Revenue Estimate is $0.27M (+80.0% Y/Y). Over the last 3 months, EPS estimates have seen 1 upward revisio...
Findings provide key insights into ATYR2810’s potential mechanism of action, including ability to modulate key immune cells involved in tumor progression, metastasis and therapy resistance. Data will support the clinical development of ATYR2810, including a Phase 1 study in...
SAN DIEGO, Nov. 03, 2021 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced that it will report third quarter 2021 financial results and provide ...
NEW YORK and VANCOUVER, British Columbia, Nov. 02, 2021 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX-V:BCT) (“BriaCell” or the “Company”) , a clinical-stage biotechnology company specializing in targeted immunotherapies for advan...
LONDON, UK / ACCESSWIRE / October 22, 2021 / Love Hemp Group PLC (AQSE:LIFE)(OTCQB:WRHLF ) , one of the UK's leading CBD and hemp product suppliers, is pleased to announce that Andrew Male, Chairman, will provide a Company Update via the Investor Meet Company platform on Monday 1 November 2...
SAN DIEGO, Oct. 11, 2021 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced that Sanjay S. Shukla, M.D., M.S., President and Chief Executive Offi...
SAN DIEGO, Oct. 06, 2021 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced the appointment of Robert W. Ashworth, Ph.D., to Vice President, Regu...
SAN DIEGO, Oct. 01, 2021 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced that the company will present a poster at the upcoming Society for Im...
aTyr Pharma produced some surprisingly strong results from recent trials of its lead drug candidate ATYR1923, and its share price has skyrocketed. ATYR1923 is indicated for Pulmonary Sarcoidosis - a ~200k patient population - but could address the $2-$3bn wider ILD market. The com...
Gainers: ZIVO Bioscience (NASDAQ:ZIVO) +71%. Aehr Test (NASDAQ:AEHR) +36%. Unique Fabricating (NYSE:UFAB) +32%. Meredith (NYSE:MDP) +26%. Paltalk (NASDAQ:PALT) +24%. Marin Software (NASDAQ:MRIN) +22%. ReWalk Robotics (NASDAQ:RWLK) +20%. Metacrine (NASDAQ:MTCR) +17%. Naked Brand Group (NASDAQ:...
News, Short Squeeze, Breakout and More Instantly...
SAN DIEGO, June 03, 2024 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE) (“aTyr” or the “Company”), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today ann...
SAN DIEGO, May 15, 2024 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE) (aTyr or the “Company”), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that the c...
Independent data and safety monitoring board (DSMB) recommends continuation of study without any modifications. Findings further support favorable safety profile of efzofitimod. SAN DIEGO, May 14, 2024 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE) (aTyr or the “Compa...